Scientific and educational activities

Scientific Meetings

EHA SWG Quality of Life and Symptoms Networking Hub Meeting

Date and location: November 7-8, 2025, Reggio Calabria, Italy

Overview of the identified decisions

The purpose of the Networking Hub meeting was to have a possibility to meet each other in person as well as via Zoom, and to deliver the results and achievements of previous and ongoing SWG projects, especially EHA Evidence-Based “Guidelines on patient-reported outcomes measurement in Hematology” to new members, to discuss SWG session program at EHA2026 Congress and to envisage future plans, future research strategy and expansion of the SWG.

Furthermore, SWG members learned about the new EHA goals and strategic plans, EHA’s Agenda 2030, Borderless Hematology.

Main priorities identified for the next 3–5 years:

  1. The future focus is on the following disorders
    • chronic myeloproliferative neoplasms
    • non-malignant hematology as paroxysmal nocturnal hemolysis and immune thrombocytopenia, autoimmune disorders
    • B-cell neoplasms
    • Pediatric hematology, both benign and malignant, will be considered
    • Palliative care will be included in the SWG structure.
    The main priority is to advertise the use of Quality of Life and Patient Reported Outcome tools in day-to-day practice to influence clinical and treatment decision-making. The HM-PRO will be considered to achieve this goal.
  2. Actions were identified to align with EHA Strategy 2030 along the following aspects:
    • Nurturing Knowledge for Collective Growth
    • Fostering an Innovative Environment
    • Advancing Research for Significant Breakthroughs
    • Pursuing Equitable Access to Enhance Patient Care
    • Empowering a Thriving Hematology Community
    Please find the identified strategy and the details of the proposed actions of the SWG on Quality of Life and Symptoms in the full report of the Networking Hub Meeting here.

European Bone Marrow Transplantation (EBMT) Annual Meeting

Date and location: March 30, 2025, Florence, Italy

Agenda:

  • Esther Oliva of London North West University Healthcare NHS Trust presented at EBMT2025.
  • The presentation title was ‘Patient involvement in designing PRO measures”

POST EHA2025 CONGRESSO ANNUALE QOL-ONE

Date and location: July 4, 2025, Reggio Calabria, Italy

Agenda:

  • Sam Salek of University of Hertfordshire, UK presented at POST EHA 2025.
  • The presentation title was Quality of life measurement in clinical practice.
  • The presentation took place on July 4, 2025, at POST EHA 2025, in Reggio Calabria, Italy.
  • Esther Oliva of London North West University Healthcare NHS Trust, UK, presented at POST EHA 2025.
  • The presentation title was EHA guidelines on patient reported outcomes in clinical trials.

Other activities

Horizon 2020-funded clinical trials in hematology

The SWG was involved in the following trials.

RESILIENCE

A trial to evaluate remote ischemic conditioning for preventing anthracycline cardiotoxicity in lymphoma patients, incorporating a significance focus on the quality of life.

RESOLVE

A project to establish the predictive value of measurable residual disease (MRD) in AML/CLL patients.

It aims to do this through:

  • The development of an MRD registry
  • The establishment of a multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients

The latter will involve individuals with AML (360 patients; five time points) or CLL (134 patients; five time points).

IMPACT

An international, multicenter, randomized pragmatic clinical trial that will compare standard chemotherapy to low-intensity therapy in relapsed or refractory AML patients

International projects involving the SWG

The SWG has been involved in the:

  • Acute Leukemia Advocates Network (ALAN) survey
  • Associazione Italiana Pazienti Sindrome Mielodisplastica (AIPASIM) survey
Share